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ABSTRACT 
 
Aim: Novel effective treatment is urgently needed for sporadic Alzheimer’s disease (sAD). 
M30  ([5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline]) and HLA-20 (5-{4-
propargylpiperazin-1-ylmethyl}-8-hydroxyquinoline) are brain permeable, iron chelating 
compounds with antioxidant activity, showing also neuroprotective activity in animal models 
of neurodegeneration. We aimed to explore their therapeutic potential in non-transgenic (non-
Tg) rat model of sAD developed by intracerebroventricular administration of streptozotocin 
(STZ-icv).  
Main methods: Therapeutic effects of chronic oral M30 (2 and 10 mg/kg) and HLA20 (5 and 
10 mg/kg) treatment on cognitive impairment in STZ-icv rat model were explored by Morris 
Water Maze (MWM) and Passive Avoidance (PA) test in neuropreventive and neurorescue 
paradigms. Data were analysed by Kruskal-Wallis and Mann-Whitney U test (p<0.05). 
Key findings: Five-day oral pre-treatment with M30 and HLA20 dose-dependently prevented 
development of spatial memory impairment (MWM probe trial-time +116%/M30; 
+60%/HLA20) in STZ-icv rat model (p<0.05). Eleven-week oral treatment with M30 
(3xweek), initiated 8 days after STZ-icv administration dose-dependently ameliorated already 
developed cognitive deficits in MWM test (reduced number of mistakes 3 months after the 
STZ-icv treatment – 59%; p<0.05) and fully restored them in PA test (+314%; p<0.05). 
Chronic M30 treatment fully restored (-47%/PHF1; -65%/AT8; p<0.05) STZ-induced 
hyperphosphorylation of tau protein and normalized decreased expression of insulin 
degrading enzyme (+37%; p<0.05) in hippocampus.  
Significance: The results provide first evidence of therapeutic potential of M30 and HLA20 
in STZ-icv rat model of sAD with underlying molecular mechanism, further supporting the 
important role of multi-target iron-chelators in sAD treatment.  
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INTRODUCTION 
 
Alzheimer's disease (AD) is a neurodegenerative disorder clinically characterized by a 
progressive memory decline. Novel and effective therapeutic approach for AD is urgently 
needed which should be tested pre-clinically in animals models that mimic familial and 
sporadic AD form (sAD). Widely exploited transgenic animal models of AD (Lithner et al. 
2011) represent the familial form of AD and do not mimic the sAD condition (Balducci and 
Forloni 2011). Animal model which develops insulin resistant brain state and glucose 
hypometabolism following the intracerebroventricular application of a betacytotoxic drug 
streptozotocin in small rodents and cynomolgus monkey (STZ-icv model), (Agrawal et al. 
2011; Grünblatt et al. 2007; Lannert and Hoyer 1998; Lee et al. 2014; Lester-Coll et al. 2006; 
Plaschke and Hoyer 1993; Salkovic-Petrisic et al. 2006), shares similarities with the human 
sAD condition (Lannert and Hoyer 1998) since insulin resistant brain state was found post-
mortem in sAD patients (Correia et al. 2011; de la Monte and Wands 2005; Frölich et al. 
1998). Additionally, STZ-icv model demonstrates also cognitive deficits (Mayer et al. 1990; 
Lannert and Hoyer 1998) and decrement in cerebral  cholinergic transmission (Blokland and 
Jolles 1993; Hellweg et al. 1992), as well as other features of chronic neurodegeneration like 
oxidative stress and neuroinflammation (Saxena et al. 2011; Sharma and Gupta 2001) and in 
particular tau protein hyperphosphorylation (Grünblatt et al. 2007; Deng et al. 2009; Liu et al. 
2014; Peng et al. 2013), pathological Aβ accumulation (Shingo et al. 2013) and cerebral 
amyloid angiopathy  (Salkovic-Petrisic et al. 2006, 2011).  
Considering the involvement of iron accumulation in AD pathophysiology (Grünblatt 
et al. 2010; Honda et al. 2004), metal chelation has become one of the therapeutic strategies 
for the treatment of AD (Budimir 2011). Deferoxamine (DFO), the natural prototype iron 
chelator/radical scavenger slowed the clinical progression of AD dementia (Crapper et al. 
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1991) and inhibited amyloidogenic processing of amyloid precursor protein (APP) and 
reversed iron-induced memory deficits and tau phosphorylation in mice model of AD (Guo et 
al. 2013a,b). Clioquinol and PBT2, 8-hydroxyquinoline bidentate ligands, attenuated 
cognitive loss and inhibited Aβ accumulation in AD transgenic mice (Cherny et al. 2001; 
Adlard et al. 2011). 
Novel anti-AD therapeutic strategies focus on drugs which target multiple pathology 
aspects of the disease (Van der Schyf et al. 2006; Youdim and Buccafusco 2005). M30 ([5-
(N-methyl-N-propargyaminomethyl)-8-hydroxyquinoline]) and HLA20 (5-{4-
propargylpiperazin-1-ylmethyl}-8-hydroxyquinoline) are multi-target compounds with iron 
chelating potency, radical scavenging activity and features of inhibition of iron-induced lipid 
peroxidation (Zheng et al. 2005). Neuroprotective activity of M30 was found in vitro and in 
some animal models of neurodegenerative disorders (Zheng et al. 2005; Weinreb et al. 2011). 
Systemic treatment of transgenic (APP/presenilin 1) mice with M30 for 9 months, attenuated 
cognitive impairments, reduced cerebral iron accumulation, modulated glucose metabolism 
and reduced APP expression, Aβ accumulation and tau phosphorylation (Kupershmidt et al. 
2012; Mechlovich et al. 2014a).  
Using the non-transgenic STZ-icv rat model of sAD, we herein aimed to assess the 
effectiveness of M30 and HLA20 in improving the cognitive deficits and underlying 
neurochemical alterations. 
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MATERIALS AND METHODS 
 
Materials 
 
Streptozotocin was purchased from Sigma-Aldrich (Munich, Germany). 5-{N-methyl-N-
propargylaminomethyl}-8-hydroxyquinoline (M30) and 5-{4-propargylpiperazin-1-
ylmethyl}-8-hydroxyquinoline (HLA20) have been provided by Eve Topf Center of 
Excellence, Technion –Faculty of Medicine, Haifa, Israel. Nuclear fast red was a gift from 
Professor Camelia Monoranu from University of Würzburg, Department of Pathology, 
Germany. 
 
Animals  
 
Three to four-month old male Wistar rats weighing 280-330 g (Department of Pharmacology, 
University of Zagreb School of Medicine) were used throughout the studies. The rats were 
kept 2-3 per cage in a room with a 12 h light/12 h dark cycle (lights on 07:00 –19:00 h), and 
the room temperature and humidity set in the range of 21–25°C and 40–70% respectively.  
Standardized food pellets and water ad libitum were provided to all animals. Animal care and 
experiments were performed in accordance with the Guidelines for the Care and Use of 
Laboratory Animals (8th ed. 2011) and the protocol was approved by the institutional Ethical 
Committee. Animals were euthanized after cognitive testing at the end of experiments in deep 
anaesthesia (thiopental 50 mg/kg/6 mg/kg diazepam intraperitoneally) followed by 
decapitation. All studies involving animals are reported in accordance with the ARRIVE 
guidelines for reporting experiments involving animals (Kilkenny et al. 2010). 
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STZ-icv rat model 
 
Rats were given general anaesthesia (chloral hydrate 300 mg/kg, ip), followed by injection of 
streptozotocin 1 mg /kg (single dose) or 3 mg/kg (split in two doses on day 1 and 3) 
administered bilaterally into the left and right lateral ventricle as previously described 
(Grünblatt et al. 2007; Salkovic-Petrisic et al. 2006, 2011). Drug concentration and solution 
volume were adjusted according to the animal body weight, and a volume of 4 μL per 300 g 
body weight was administered (2 μL/ventricle). Control animals received bilaterally an equal 
volume of vehicle (0.05 M citrate buffer pH 4.5) into the lateral ventricles. Appropriate care 
was taken during anaesthesia and recovering period to reduce the pain and discomfort as 
much as possible. STZ-icv treated animals were randomly allocated to receive iron-chelator or 
saline. 
 
Iron-chelator treatments 
 
HLA20. Neuropreventive paradigm was tested by pre-treatment with saline, or HLA20 (5 
mg/kg/day), administered by oral catheter (adjusted for volume of 1 mL/300 g body weight) 
for 5 days (9:00 to 10:00 h). On the 5
th
 day, a single STZ-icv (1 mg/kg) or vehicle-icv 
injection was given after the last HLA20 oral dose. Animals were sacrificed 1 month 
following the STZ- or vehicle-icv treatment. In additional experiment, rats were pre-treated 
for 5 days with HLA20 (10 mg/kg/day), similarly as in the previous experiment, but were 
sacrificed 3 months following the STZ-icv injection.  
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M30. Neuropreventive paradigm was tested by pre-treatment with saline or M30 (10 
mg/kg/day), administered by oral catheter (1 mL/300 g body weight) for 5 days (9:00 to 10:00 
h). On the 5
th
 day, a single STZ-icv (1 mg/kg) or vehicle-icv injection were given after the last 
M30 dose and animals were sacrificed 1 month later. 
 
M30. Neurorescue paradigm activity was tested by post-treatment with M30 administered in 
two doses (2 and 10 mg/kg/day, on Monday, Wednesday and Friday during each treatment 
week) by oral catheter (1 mL/300g body weight), for 11 weeks (9:00 to 10:00 h), starting 
from the 8
th
 day following the first (out of two) STZ-icv injection (3 mg/kg). Control STZ-icv 
rats were orally treated by saline in a similar way. All animals were sacrificed 3 months 
following the first STZ-icv injection. Additional short-term experiment of a similar design 
was performed to test the activity of high (10 mg/kg/day) M30 dose on neurochemistry 
parameters (control, STZ and STZ+M30 group). Oral M30 treatment was initiated from the 
8
th
 day following the first (out of two) STZ-icv injection (3 mg/kg) and animals were 
euthanized a week later, after being administered with 3 M30 doses only (on Monday, 
Wednesday and Friday).  
 
Cognitive performance assessment  
 
Cognitive performance assessment was done by Morris Water Maze Swimming test (MWM, 
8:00-13:00 h), which tests spatial memory, and Passive Avoidance (PA, 8:00-9:00 h) test, 
which tests fear-motivated avoiding memory. In the M30 neuropreventive paradigm MWM 
was performed once before the sacrifice, while in the M30 neurorescue paradigm, MWM was 
performed repeatedly after 2 weeks and 1, 2 and 3 months post- STZ-icv injection and PA 
was performed only once before the sacrifice. In the HLA20 -5 mg/kg neuropreventive 
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paradigm, MWM and PA were performed once before the sacrifice, while in another HLA20 - 
10 mg/kg neuropreventive paradigm, MWM was performed repeatedly after 2 weeks and 1, 2 
and 3 months post- STZ-icv injection. No cognitive testing was done in a short-term 
experiment in neurorsecue paradigm. 
 
MWM Test 
On the first day of adaption to the environment, rats were subjected to 1 min of freely 
swimming in a pool (150x60 cm, 50 cm deep), with water temperature set at 25±1 oC, and on 
the second day rats were allowed to freely swim in the pool divided in four compartments (I-
IV). The acquisition or training phase was performed afterwards from day 1 to day 4, during 
which the rats were thought to escape from water by finding a hidden rigid platform 
submerged about 2 cm below the water surface in compartment IV. Stay on the platform was 
allowed for 15 s. One training trial consisted of three starts, each from a different 
compartments (I – III), separated by a 1-min rest period. Three consecutive trials were 
performed per day, separated by a 30-min rest period. Escape latency (time needed to find the 
platform) and number of errors (entries into the compartments without a platform) were 
recorded as parameters of the reference memory (memory acquisition). After the third training 
trial on day 4, the probe trial was performed (starts from compartments I-III) with a platform 
being removed from the pool, and the time spent within the compartment IV (from which the 
platform was removed) and the number of errors were recorded as parameters of the working 
memory (memory retention). The cut off time was 1 min. 
 
PA test 
The rats were placed in a light compartment of a shuttle box (Ugo Basile, Comerio, Italy) on 
the 1
st
 test day for acclimatization. The light compartment has been isolated from the dark 
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compartment by a guillotine door which is closed automatically after entry of the rat into the 
dark compartment. On the 2
nd
 test day, during the acquisition trial, animals were placed again 
into the light compartment and after entry into the dark compartment, received a low-intensity 
electric foot shock (0.5 mA; 2 s) delivered through the grid metal floor in the dark 
compartment. During the retention trial, animals were again placed in the light compartment 
and the post-shock latency time spent within the light compartment before entering the dark 
one was recorded.  
 
Western blot analysis 
 
Tissue preparation.  
Hippocampal (1 animal = 1 sample) tissue samples from one half of the rat brain were 
homogenized with 3 volumes of lysis buffer containing 10 mM HEPES, 1 mM EDTA, 100 
mM KCl, and 1% Triton X-100, pH 7.5, and protease inhibitors coctail (1:100), and the 
homogenates were centrifuged at 12000 rpm for 10 min at 4°C and the supernatant were 
frozen and stored at -80°C. Protein concentration was measured by Lowry protein assay.   
Immunoblotting.  
Equal amounts of total protein (35 μg per sample) were separated by SDS-PAGE using 9% 
polyacrylamide gels and transferred to nitrocellulose membranes. The nitrocellulose 
membranes were blocked by incubation in 5% non-fat milk added to low salt washing buffer 
(LSWB) containing 10 mM Tris and 150 mM NaCl, pH 7.5, and 0.5% Tween 20 for one hour 
at room temperature. Blocked blots were incubated overnight at 4°C with anti-IDE (1:2000), 
anti-AT8 (1:500), anti-total tau (1:500) or overnight at RT with primary anti-PHF1 (1:500). 
Following the incubation, the membranes were washed three times with LSWB and incubated 
for 60 min at room temperature with appropriate secondary antibody solution (anti-mouse or 
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anti-rabbit IgG, 1:5000). The specificity of the signal was checked on the control membranes 
that were not incubated with the primary antibody. After washing three times in LSWB, the 
membranes were immunostained using chemiluminiscence Western blotting detection 
reagents, signal captured and visualised with the MicroChemi 2.0 CCD camera system (DNR 
Bio-Imaging Systems) and after that washed three times in LSWB and incubated with loading 
control, anti-GAPDH (1:2000) or anti-βactin (1:5000) antibody followed by the same 
procedure already mentioned above. 
 
Statistics 
 
For all experiments based on comparisons of independent groups (N=7-10 rats per group), 
data were expressed as mean±SEM and analysed using non-parametric ANOVA (Kruskal-
Wallis) followed by Mann-Whitney U-test, or by parametric ANOVA followed by Tukey 
HSD test. Data from the 3-month experiment with repeated MWM testing in the same 
animals were analysed by fitting generalized linear mixed models with Poisson (for the 
number of errors) or normal (latency times) link function. All tests were adjusted for multiple 
comparisons in order to keep the experiment wise alpha level at 0.05, and p<0.05 was 
considered statistically significant. 
 
 
Ethics 
 
Animal procedures, carried out at the University of Zagreb Medical School (Zagreb, Croatia), 
were as human as possible, as described in details in the section “Material and Methods“ in 
compliance with the recommendations of ARRIVE. All analyses were done in compliance 
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with valid institutional, national (The Animal Protection Act, NN135/06) and international 
(Directive 2010/63/EU) guidelines governing the use of experimental animals and have been 
approved by the national regulatory body responsible for issuing ethical approval, Croatian 
Ministry of Agriculture (licence No. UP/I-322-01/11-01/100 to MSP for research approved by 
Croatian Ministry of Science, Education and Sport, project 108-1080003-0020 to MSP).  
 
RESULTS 
 
Effect of M30 on STZ-icv-induced memory impairment 
 
Neuroprevention 
 
In comparison to control animals, STZ-icv treatment induced memory impairment in rats, as 
detected in the probe MWM trials, 1 month after the treatment (Fig. 1A). STZ-icv treated rats 
had a poor memory on the location of the compartment with a platform and thus had more 
entries into the incorrect compartments (increased number of mistakes, p<0.05), spending less 
time swimming within the targeted compartment from which the platform had been 
previously removed, p<0.05 (Fig. 1B). Five-day oral pre-treatment with M30 (10 mg/kg/day) 
significantly prevented development of spatial memory impairment in STZ-icv treated rats, 
which was manifested by reducing the number of mistakes (Fig. 1A) and increasing the time 
spent within the targeted compartment (Fig. 1B) in the MWM probe trial, in comparison to 
the STZ-icv treatment alone. Pre-treatment with the lower M30 dose (5 mg/kg/day) was 
ineffective (data not shown). No significant difference was detected between M30-treated and 
vehicle-treated control rats in error number and the time spent within the compartment (Fig. 
1). 
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Neurorescue 
 
The therapeutic potential of M30 on spatial learning and memory impairment, as well as on 
fear motivated escape memory deficits in STZ-icv rat model of sAD, has been also tested in a 
neurorescue experimental design by MWM and PA test, respectively.  
 
MWM test 
 
Learning and memory performance in training trails over time.  A total of 4/33 animals died 
during the course of the experiment (Fig. 2, bottom): one animal in the control group, one in 
the STZ+ M30 (2 mg/kg) group and 2 animals in the STZ + M30 (10 mg/kg) group. On the 
4
th
 day of each of the 4-day training cycles (after 2, 4, 8 and 12 weeks since the last STZ-icv 
administration), the number of errors appeared lower (Fig. 2A) and escape latency time 
shorter (Fig. 2C), than those on the 1
st
 day of each respective cycle, indicating the ability to 
learn through training (learning capacity), with following particulars: a) the largest differences 
(day 4 vs. day 1) appeared 2 weeks after STZ-icv administration and progressively decreased 
in repeated training cycles, indicating reduced space for improvement due to lower starting 
(day 1) values in later cycles; b) the reduction of day 1 values indicated development of 
memory; c) after 2 weeks, differences at day 4 vs. day 1 appeared to be greatest in control and 
smallest in STZ-icv treated animals, indicating impaired learning capacity in the latter, 
whereas M30-treated STZ-icv rats apparently performed poorer than controls, but better than 
STZ-icv treated animals. This relation was maintained throughout the experiment; d) 
similarly, reduction of day 1 values appeared most pronounced in controls, least pronounced 
in STZ-icv treated animals (indicating STZ-icv induced impairment), while the performance 
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of M30-treated STZ-icv rats appeared “intermediate”. Initial formal statistical tests referred to 
all 16 assessments (4 in each of the 4 cycles) and demonstrated the following: a) the number 
of errors was markedly higher in STZ-icv-treated vs. control animals (RR=34.8, p<0.001) 
(Fig. 2B); b) M30 dose-dependently antagonized the STZ-icv-effect; differences vs. control 
were still significant but lower, and the number of errors was lower, as compared to STZ-icv-
treated rats: RR=0.68, p<0.001 and RR=0.25, p<0.001, for M30 (2 mg/kg and 10 mg/kg), 
respectively (Fig. 2B). The effects of the treatments on escape latency time followed the same 
pattern (Fig. 2C). As shown in Fig. 2D, when escape latency was analysed with adjustment 
for the number of errors (as a time-varying covariate), no major effect was observed, 
indicating that the main effect was on number of entries into incorrect compartments (number 
of errors) resulting in longer time needed to escape from water onto the platform. Therefore, 
specific statistical evaluation of learning capacity over time and long-term 
acquisition/retention of memory focused on the number of errors. The main points are 
summarized in Table 1. Controls retained constant relative learning capacity throughout the 
experiment. STZ-icv-treated rats had significantly reduced learning capacity (vs. controls) in 
the 1
st
 (p<0.001) and 2
nd
 (p=0.029) cycles, but with repeated trainings, the capacity increased 
and was, in relative terms, close to that in controls, yet at a higher absolute level of the 
number of errors. M30 (10 mg/kg) antagonized STZ-icv-induced impairment. Day 1 values 
decreased over time (cycles) in all groups (development of memory), but markedly more in 
controls than in STZ-icv-treated rats (p<0.001). The decrease with M30 (2 mg/kg) was similar 
to that of STZ-icv alone (p=0.480), but less than in controls (p=0.003), while the decrease 
with M30 (10 mg/kg) was similar to that in control animals (p=0.122) and significantly more 
pronounced than in STZ-icv-treated rats (p=0.010) (Fig. 2E). In summary, the data illustrate 
an impairing effect of STZ-icv on memory acquisition/retention that is antagonized by the 
higher M30 dose. Furthermore, the difference between STZ-icv-treated and control rats 
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progressively increased across the four cycles from RR=2.03, p=0.005 to RR=18.4, p<0.001, 
indicating a time-dependent enhancement of STZ-icv-induced impairment. At the same time, 
the difference between M30 (10 mg/kg)-treated STZ-icv rats and vehicle-treated STZ-icv rats 
also progressively increased across the four cycles from RR=0.68, p=0.213 to RR=0.13, 
p=0.026, indicating a time-dependent enhancement of the beneficial effect of M30 on STZ-
icv-induced impairment. 
 
Memory performance in the probe trial over time. Performance in the MWM probe trials 
during 3 months after STZ-icv administration revealed a significant deficit in spatial memory 
of STZ-icv rats, in comparison to the controls at all time-points, demonstrated as higher 
number of mistakes (p<0.05) and shorter time spent within the targeted compartment (p<0.05) 
(Fig. 3). Time-course data, recorded in the probe trials within the STZ-icv group support the 
above-mentioned limited capacity of retaining the spatial memory; STZ-icv rats have retained 
limited  memory of the pathway to the platform making less incorrect entries as the repetition 
of MWM trials increased in the course of 2 and 3 months after STZ-icv treatment (p<0.05) 
(Fig. 3A). In the STZ-icv-treated group, the tendency for limited improvement in the course 
of time is seen in the time spent in targeted compartment, which however, has not reached the 
significant level (Fig. 3B). Treatment with M30, initiated 8 days after STZ-icv, ameliorated 
STZ-induced memory deficits, affecting primarily the number of mistakes in the MWM probe 
trial (Fig. 3A). The number of mistakes in M30 (10 mg/kg)-treated STZ-icv group was 
significantly reduced (p<0.05) in comparison to STZ-icv treated rats, at 2 weeks and 2 and 3 
months following the STZ-icv administration (Fig. 3.3A). The effect was clearly dose-
dependent, as the STZ-icv group treated with M30 (10 mg/kg) demonstrated significantly 
reduced number of mistakes, compared to that observed in the group treated with the lower, 2 
mg/kg M30 dose, which was ineffective in this respect (Fig. 3A). However, both M30 doses 
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were almost ineffective in increasing the time within the targeted compartment in STZ-icv 
treated rats, with the exception of the 2-month time-point, when a significant increase was 
achieved with the high M30 dose, in comparison to the STZ-icv treatment alone (Fig. 3B). 
Failure of the high M30 dose to increase the time spent within the targeted compartment at 3-
month time point might be related to the number of animals in this group at that time point. 
Similar to the control group, the STZ-icv group treated with the higher M30 dose 
demonstrated preserved capability to retain memory over time, as shown by increased time 
spent in targeted compartment after 1 and 2 months in comparison to 2 weeks after STZ-icv 
treatment (p<0.05) (Fig. 3B). This beneficial effect was missing in STZ-icv group treated with 
a low M30 dose (Fig. 3B). 
 
PA test 
 
Eleven-week long treatment with M30 (10 mg/kg), initiated 8 days following the STZ-icv 
injection, successfully restored STZ-icv induced impairment in fear-motivated escape 
memory in PA test (Fig. 4), while M30 (2 mg/kg) was ineffective in this respect, as latency 
time remained similar to STZ-icv treatment alone (Fig. 4). 
 
Neuropreventive effect of HLA20 on STZ-icv-induced memory impairment 
 
Further experiments have been performed in order to examine the effect of HLA20, a 
chemically different multifunctional compound, which shares the iron-chelating activity with 
M30, on STZ-icv-induced cognitive deficits. 
Five-day oral pre-treatment with HLA20 (5 mg/kg) significantly decreased the number of 
mistakes in the MWM probe trial (Fig. 5A) and increased the time spent within the targeted 
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compartment (Fig 5B), in comparison to the STZ-icv treatment alone (p<0.05).  HLA20 (5 
mg/kg) also prevented STZ-icv-induced impairment in fear-motivated escape memory in the 
PA test, measured 1 month after STZ-icv treatment and increased latency time (p<0.05), 
compared to the STZ-icv treatment alone (Fig. 5C). Oral pre-treatment with a higher, HLA20 
dose  (10 mg/kg) exerted a neuropreventive effect in STZ-icv-treated rats in the MWM probe 
trial already after 2 weeks, seen both as less entries into the incorrect compartments (Fig. 6A) 
(p<0.05) and longer time (Fig. 6B) (p<0.05) within the targeted compartment, in comparison 
to the STZ-icv treated rats. The latter effect of HLA20 was persistent up to 3 months after 
STZ-icv treatment, while the significance of the former vanished in the course of time (Fig. 
6A). HLA20 to buffer-icv-treated rats had no effects on cognitive performance, compared to 
control rats, with the exception of the beneficial effect (reduction of mistake number) seen of 
2 weeks (Fig. 6A).  
 
Beneficial effect of M30 on STZ-induced decrement in IDE level and on tau 
hyperphosphorylation  
 
Possible molecular mechanisms underlying M30 beneficial effects on cognitive performance 
in the neurorescue paradigm were explored at the level of IDE and tau protein (AT8/PHF1), 
two parameters which build up the pathophysiological core of AD.  
 
While IDE expression in hippocampus was found unaffected 2 weeks after STZ-icv 
treatment, it was significantly decreased (-21%, p<0.05) after 3 months (Fig. 7A, F). Long-
term treatment with both low and high M30 dose in neurorescue paradigm significantly 
increased IDE expression in comparison to the STZ-icv treatment alone (+19% and +37%, 
p<0.05) and normalized it to the levels of controls (Fig. 7A, F). 
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Compared to controls, significant increase in PHF1 phospho tau expression and in PHF1 
phospho/total tau ratio was detected 2 weeks (+328% and +461%, p<0.05) and 3 months 
following STZ-icv administration (+120% and +215%, p<0.05) (Fig. 7B, C, G, H). Long-term 
treatment with high M30 dose (10 mg/kg) in the neurorescue paradigm completely 
normalized STZ-induced increment in both PHF1 expression (p<0.05) and PHF1/total tau 
ratio (p<0.05) to the control levels, measured 3 months after STZ-icv administration (Fig. 7G, 
H). Low M30 dose was ineffective in this respect (Fig. 7G, H). This beneficial effect of high 
dose begun to be manifested already after a week of M30 treatment (i.e. 2 weeks after STZ-
icv treatment) when significantly reduced STZ-induced increment in PHF1/total tau protein 
ratio (-42%, p<0.05) was found in comparison to STZ treatment alone (Fig. 7C). Long-term 
treatment with high M30 dose (10 mg/kg) significantly decreased AT8 phospho tau 
expression in STZ-icv treated rats (-34% and -60%, p<0.05 vs control and STZ), although at 
that time point, a tendency of STZ-induced increment in AT8 expression did not reach the 
level of significance (Fig. 7D, E, I, J). 
 
DISCUSSION  
 
Numerous clinical AD trials failed to confirm the effectiveness of drugs tested so far 
(Mangialasche et al. 2010) which, among other reasons, could be due to focusing on the 
inappropriate mechanism of drug action based on the incorrect understanding of the primary 
pathophysiological core of the disease. Mechanisms of action, other than those affecting 
primarily Aβ homeostasis or  tau phosphorylation and assembly,  which have all targeted a 
single pathological process (Salomone et al. 2012), have been rather neglected. Additionally, 
a growing body of evidence indicates that there might be different sAD endophenotypes (e.g. 
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apolipoprotein E positive and negative
 
individuals) (Borroni et al. 2006), suggesting that 
choosing the animal model, which mimics a specific endophenotype (e.g. “brain insulin 
resistance” endophenotype) might contribute to a more successful translation of the results to 
the corresponding endophenotype of sAD population (Zahs et al. 2010). 
Considering the diverse etiological nature of AD forms, novel therapeutic strategies should be 
focused on the implementation of drugs directed to various neuronal targets to address the 
multiple pathology aspects of the disease (Van der Schyf et al. 2006; Youdim and Buccafusco 
2005). The homeostasis of brain iron is thought to be necessary for normal brain function, 
especially in learning and memory (Youdim et al. 1989). Disruption in iron metabolism and 
pathological iron accumulation in the brain have been postulated to have a role in the 
pathogenesis of AD (reviewed by Grünblatt et al. 2010), suggesting that iron-chelating drugs 
might have a beneficial therapeutic effect in AD. M30 and HLA20, have been developed as 
multifunctional compounds whose molecule consists of propargylamine, the active 
neuroprotective moiety of rasagiline, embedded in the backbone of the antioxidant-iron 
chelator 8-hydroxyquinoline derivative of VK-28 (Ben-Shachar et al. 2004; Zheng et al. 
2005). Previously, iron-complexing agents have been suggested as a promising therapeutic 
strategy for the treatment of AD (Crapper et al. 1991; Ritchie et al. 2003). However, these 
compounds are either toxic or do not penetrate the blood brain barrier (Ritchie et al., 2003), 
while M30 and HLA20 have been developed as multi-targeting non-toxic, brain permeable 
drugs, which exert iron chelating potency, radical scavenging and inhibition of iron-induced 
membrane lipid peroxidation features. M30 and HLA20 were found to confer neuroprotective 
activity in various in vitro and in vivo animal models of neurodegenerative disorders (Ben-
Shachar et al. 2004; Kupershmidt et al. 2012; Zheng et al. 2005).  
The presented results have demonstrated that M30 exerted neuroprotective activity by 
completely preventing the development or ameliorating already developed cognitive deficits 
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in STZ-icv-treated rats in the preventive and neurorescue paradigms, respectively. Regardless 
the experimental paradigm, this beneficial effect of M30 has been clearly dose-dependent and 
increased in extent with the duration of drug treatment. The differences in the effectiveness of 
M30 on various parameters of reference and working memory measured in the MWM trials 
are in line with their different sensitivity to the STZ-icv injection. Thus, both the toxic effect 
of STZ-icv treatment and the beneficial activity of M30 were more prominent on the number 
of mistakes, either in training or in probe trials. M30 treatment was found to be less effective 
in improving the working than the reference memory, presumably as working memory seems 
to be more sensitive (impaired to a greater extent) following the STZ-icv treatment. However, 
M30 eventually restored memory acquisition in the training trials and escape latency in the 
PA test to the levels of controls. The reasons for that could not be elucidated by our research 
and are likely associated with different sensitivity of hippocampal subregions involved in 
processing various types of memory (Morris et al. 2012; Xavier et al. 1999); it was shown that 
different types of cognitive disruptions occur following STZ-icv injection with distinct time 
courses (Salkovic-Petrisic et al. 2012; Santos et al. 2012). Considering that similar beneficial 
effect on STZ-icv-induced memory impairment was observed with another multifunctional 
iron-chelating agent (HLA20) and also with the iron-chelator VK-28 (data not shown), iron-
chelation seems to be crucial for the cognitive improvement effect of M30 in this model.  
 
The exact mechanism by which STZ-icv treatment impairs cognitive functions still needs to 
be elucidated, but factors like direct neurotoxicity, brain glucose/energy and cholinergic 
deficits, oxidative stress and insulin resistant brain state, may all form the biological basis for 
the marked reduction in learning and memory capacities found in this model. STZ generates 
intracellular free radicals, nitric oxide and hydrogen peroxide (H2O2), and is selectively toxic 
for insulin producing/secreting cells (Szkudelski 2001). Regarding the antioxidant properties 
21 
 
of M30, recent studies demonstrated that the drug attenuated H2O2-induced mitochondrial 
membrane potential loss and displayed significant cytoprotective activity against cytotoxicity 
induced by oxidative stress in insulin producing beta-cells (Mechlovich et al. 2010). 
Therefore, neuroprevention in the M30 pre-treatment studies could be related to the 
antioxidative activity of M30 against acute STZ-icv-induced oxidative stress. Indeed, our 
preliminary data showed that M30 pretreatment prevented STZ-icv-induced decrement in 
hippocampal catalase activity (Sofic et al. 2014). However, therapeutic effects of M30 in the 
neurorescue design could be related, in addition to the antioxidant activity, also to the iron-
chelating beneficial effect on the pathological processes developed after the STZ-icv 
administration. This effect might be only speculated considering the fact that there are no 
literature data on iron homeostasis in the brain of STZ-icv rat model, but our preliminary 
results of Prussian blue iron staining of brain slices obtained 3 months after icv treatment 
indirectly support the iron-chelating activity of M30 in this model. The analysis revealed a 
positive signal of ferric iron in the brain mostly in the path of the needle insertion during the 
icv injection with a mild to moderate intensity in the control (buffer-icv) and the very 
intensive, more widely distributed signal in the STZ-icv treated rats (Supplementary 
material). These changes, which seem to reflect the post-haemorrhage condition induced by 
mechanical/chemical brain damage, were significantly and dose-dependently ameliorated by a 
long-term oral M30 treatment in the STZ-icv treated rats. 
 
Recent reports have indicated that M30 exerted various beneficial neuroprotective regulatory 
effects that might be attributed to the multimodal design paradigm of the drug; including up 
regulation of insulin/insulin receptor/phospho-glycogen synthase kinase β levels, activation of 
hypoxia-inducible factor-1 pathway, and antioxidation (Mechlovich et al. 2014a,b). It was 
reported that M30 significantly reduced iron accumulation in the cortex of aged mice 
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(Kupershmidt et al. 2012). Our results have confirmed the previous finding in transgenic mice 
AD model (Kupershmidt et al. 2012) that the mechanism of beneficial M30-induced cognitive 
effects might be related to normalization of tau protein hyperphosphorylation in the 
hippocampus of the non-Tg rat sAD model. This is probably an indirect effect of M30 shown 
to affect kinases directly involved in regulation of homeostasis of tau protein phosphorylation 
(Kupershmidt et al. 2012). However, we proposed here for the first time an additional 
mechanism of action and a new possible target for M30 by demonstrating that long-term M30 
oral treatment normalizes reduced hippocampal IDE levels. IDE is a metalloprotease 
responsible for degradation of both insulin and Aβ, and reduced IDE levels in sAD leading to 
decreased Aβ degradation significantly contribute to the disease pathophysiology. Literature 
data indicate that iron-induced oxidative stress inactivates IDE (Shinall et al. 2005) which 
might provide an explanation why iron-chelators like M30 could have beneficial effect at the 
level of IDE, as detected in our experiments for the first time. Decreased IDE protein and 
gene expression has been found in STZ-icv rat model also by others (Yang et al. 2014), but 
our recent 9-month follow up data on staging of cognitive, neuropathological and 
neurochemical changes in STZ-icv rat model has shown that the order of pathology 
appearance after STZ-icv treatment is: tau protein/2 weeks, IDE/1 month, and amyloid β/3 
months (Osmanovic Barilar et al. 2015; Knezovic et al. 2015), which supports the results 
presented here. 
 
Control of iron homeostasis in the brain, as achieved by iron-chelating agents like M30, might 
be also important considering the fact that Aß-upregulation is inducible by two iron-
dependent pathways:  
(1) iron induces ROS generation, which, via stimulation of the expression of tissue inhibitor 
of metalloproteinase-2 (TIMP2), blocks α-secretase and thus provokes β-/γ-secretase induced 
23 
 
Aß production. In addition, increased ROS species shift cytoplasmatic aconitase to iron 
regulatory protein 1 (IRP-1), which stimulates cells to enhance iron uptake due to the wrong 
IRP-1 induced message of an existing iron deficiency.  
(2) iron accumulation down-regulates a proconvertase furin, thus impairing the processing of 
ADAM 10 and TACE, two metalloproteases that show α-secretase activity and are involved 
in sAPP production (Silvestri and Camaschella 2008). Moreover, the proprotein convertase 
furin promotors reveal the presence of putative binding sites for hypoxia-inducible factor-1 
(HIF-1), a transcription complex that plays a pivotal role in cellular adaptation to hypoxia 
(Mc Mahon et al. 2005) and thus offers another link to iron induced pathology (Crichton et al. 
2011). 
 
CONCLUSION  
 
In summary the multifunctional iron-chelating agent M30 demonstrates neuropreventive and 
neurorescue activity in restoring/ameliorating cognitive deficits in a non-transgenic STZ-icv 
rat model of sAD. M30-induced restoration of tau hyperphosphorylation and normalization of 
reduced IDE level in hippocampus might be responsible for M30 beneficial cognitive effects. 
These data provide further support to the therapeutic potential of multi-target iron-chelating 
agents in sAD treatment. The advantages of using an AD model with no Aβ- or tau-related 
gene modification, such as the STZ-icv rat model, in comparison to the transgenic mice AD 
models, is additionally achieved by possibility to define the exact time of the induction of 
brain damage and accordingly to successfully explore the efficacy of the novel treatment 
initiated at different time-points before or after the STZ-icv-induced brain damage. 
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FIGURE LEGENDS 
 
Fig. 1 Effect of pre-treatment with M30 on STZ-icv induced cognitive deficits. The top-
shaded panel depicts the neuropreventive experimental design: rats were pre-treated with M30 
(10 mg/kg/day), administered p.o. for 5 days. STZ-icv (1 mg/kg) or buffer-icv (CTR) 
injection was given after the last M30 dose on the 5
th
 day (N = 7 / group). Number of mistakes 
(A) and time spent within the targeted quadrant (B) were recorded in the MWM probe trial, 4 
weeks following the STZ-icv treatment. Each bar represents mean±SEM. *p<0.05 vs STZ-icv 
and #p<0.05 vs CTR by Kruskal-Wallis ANOVA median test followed by Mann Whitney U 
test. 
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Fig. 2 Effect of M30 on STZ icv-induced cognitive deficits in the neurorescue paradigm. 
The top-shaded panel depicts the experimental design: rats were injected with STZ-icv (3 
mg/kg) or buffer icv (CTR) on 2 consecutive days and administered with M30 (2 mg/kg or 10 
mg/kg p.o. 3x week) started on the 8
th
 day after the second icv injection and lasted for 12 
weeks. Animals were evaluated in the MWM test in daily training trials (4 consecutive days, 
indicated as “assess day”) at 2 weeks (days 14-17; all N = 8/group except 10/ group in control 
(CTR) group), 4 weeks (days 28-31; all N = 8/group except 9/group in CTR and 7/group in 
STZ+M30 (10mg/kg)), 8 weeks (days 56-59; 9/group in CTR, 8/group in STZ, 7/group in 
STZ+M30 (2mg/kg) and 6/group in STZ+M30 (10mg/kg)) and 12 weeks (days 84-97; 
9/group in CTR, 8/group in STZ, 7/group in STZ+M30 (2mg/kg) and 5/group in STZ+M30 
(10mg/kg)) after the last STZ-icv injection. A subsequent PA test was followed. (A) Number 
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of errors and (C) escape latency in MWM training trials over time. Each point represents the 
geometric mean of the cumulative number of errors/cumulative escape latency (s) of 9 trials 
per animal. The number of animals per group at the start of each training cycle is depicted at 
the bottom. Data for the 1
st
 day of each cycle are shown (B,D,E). A generalized linear mixed 
model (Poisson) (treatment, time, treatment*time interaction) was fitted to number or errors 
(B), and a linear mixed model was fitted to Ln(latency time) (treatment, time, treatment*time 
interaction) without (D) or with (E) further adjustment for the number of errors (a time-
varying covariate). Treatment effects are presented as relative risks (RR) (errors) or geometric 
mean ratios (GMR) (latencies) with 95% confidence intervals and p-values. Estimates were 
adjusted for multiple comparisons. 
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Fig. 3 Effect of M30 on memory retention in STZ-icv treated rats in the neurorescue 
paradigm. Treatment with M30 (2 and 10 mg/kg, p.o. 3x a week) was initiated at 8
th
 day 
following the last STZ-icv (3 mg/kg) injection and continued for 11 weeks. Control animals 
(CTR) were treated icv with buffer. Probe trail was performed after removing of the platform 
on the 4
th
 day after the last training trial, 2 weeks, 1-, 2-, and 3 months following STZ-icv 
treatment (N/group at particular time point are as described in Fig. 3.2), and number of 
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mistakes (A) and time spent in targeted quadrant (B) were recorded. Each point represents 
mean±SEM. *p<0.05 vs CTR at the respective time-point; #p<0.05 vs STZ-icv at the 
respective time-point; $p<0.05 vs STZ+ M30 (2 mg/kg) at the respective time-point; all 
analysis done by Kruskal-Wallis ANOVA median test followed by Mann Whitney U test. 
+p<0.05 vs 2 week-value of the respective group, by non-parametric Friedman test followed 
by Wilcoxon Signed-Ranks test. 
 
Fig. 4 Effect of M30 on cognitive performance as measured by the post-shock latency 
time in PA test in STZ-icv rats in the neurorescue paradigm. Treatment with M30 (2 and 
10 mg/kg, p.o. 3x week) was initiated 8
th
 day following the last STZ-icv injection (3 mg/kg) 
and was continued for 11 weeks. Control (CTR) animals were treated icv with buffer. Number 
of animals: 9/group in CTR, 8/group in STZ, 7/group in STZ+M30 (2mg/kg) and 5/group in 
STZ+M30 (10mg/kg). PA test was performed before sacrifice, 12 weeks following STZ-icv 
treatment, and escape latency (seconds) was recorded on the 3
rd
 day of testing. Each bar 
represents mean±SEM value. *p<0.05 vs STZ-icv; #p<0.05 vs CTR and $p<0.05 vs STZ + 
M30 (2 mg/kg) by Kruskal-Wallis ANOVA median test followed by Mann Whitney U test. 
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Fig. 5 Effect of pre-treatment with HLA20 on STZ-icv-induced cognitive deficits. Rats 
(N=9/group in CTR and CTR+HLA20, and 10/group in STZ and STZ+HLA20) were pre-
treated with vehicle or HLA20 (5 mg/kg/day), p.o. administered for 5 days. STZ-icv (1 
mg/kg) or buffer-icv (CTR) injection was given after the last HLA-20 dose on the 5
th
 day. 
Number of mistakes (A), time spent within the targeted quadrant (B) and post-shock latency 
(C) were recorded 4 weeks following the STZ-icv injection. Each bar represents mean±SEM. 
*p<0.05 vs STZ-icv and #p<0.05 vs CTR by Kruskal-Wallis ANOVA median test followed 
by Mann Whitney U test. 
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Fig. 6 Duration of the neuropreventive effect of HLA20 in the STZ-icv-induced cognitive 
deficits. Rats (N=9/group in CTR and STZ, and 10/group in CTR+HLA20 and STZ+HLA20) 
were pre-treated with HLA20 (10 mg/kg/day) p.o. administered for 5 days. STZ-icv (1 mg/kg) 
or buffer-icv injection (CTR) was given after the last HLA-20 dose on the 5
th
 day. MWM test 
was performed 2 weeks, 1 and 3 months following STZ-icv treatment. Number of mistakes 
(A) and time spent within the targeted quadrant (B) were recorded in the MWM probe trial. 
Each bar represents mean±SEM. *p<0.05 vs STZ-icv, #p<0.05 vs CTR and  $p<0.05 vs CTR 
+ HLA20 (10 mg/kg) by Kruskal-Wallis ANOVA median test followed by Mann Whitney U 
test. 
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Fig. 7. Western blot analysis of IDE and phosphorylated tau protein in the hippocampus 
of STZ-icv treated rats following the short- and long-term administration of M30. 
Treatment with M30 (p.o. 3x week) was initiated 8
th
 day following the last streptozotocin 
(STZ) injection (3 mg/kg) and was administered for 1 week in a 2 week-experiment, and for 
11 weeks in a 3 month-experiment (neurorescue paradigm). Western blot analysis of insulin 
degrading enzyme (IDE) (A, F) and tau protein (B-E, G-J) expression was performed in 
hippocampal (HPC) tissue samples. Tau protein phosphorylation status is expressed as 
phospho tau level (B, D, G, I) and phospho/total tau ratio (C, E, H, J) by means of AT8 
(Ser202/Thr205 phospho-tau), PHF1 (Ser 396/404 phospho tau) and anti-total tau antibodies. 
Anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and anti-β actin were used as 
loading controls. Number of animals: 6/group (control /CTR/, STZ, STZ+M30). Each bar 
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represents mean±SEM value. *p<0.05 by Kruskal-Wallis ANOVA median test followed by 
Mann Whitney U test. 
 
Table 1. Summary of the effects of M30 on long-term memory retention and learning 
capacity over time in STZ-icv rats (experiment depicted in Fig. 2).  
Outcome  Results  Conclusions 
Long-term learning 
capacity. 
Considered were 
differences Day 4 - 
Day 1 for each 
training cycle.* 
 Control: reduction of NoE in 1
st
 cycle ( 9.8, 
p<0.001) progressively decreased (= -3.16, 
p=0.021) to insignificance in further cycles. 
With adjustment for day 1 NoE, reduction 
consistently 7.0-7.5 in all cycles (all adjusted 
 p<0.001). STZ: in all cycles reduction non-
significant ( 3.8-4.3, all p>0.05). With 
adjustment for day 1 NoE,  progressively 
changed from increase (by 4.4, p=0.019) to 
reduction (by 6.2, p<0.001) from 1
st
 to 4
th
 
cycle (=-4.3, p<0.001). Reduction less than 
in Control in 1
st
 (adjusted  p<0.001) and 2
nd
 
cycle (adjusted  p=0.029), differences in 
later cycles smaller, non-significant. STZ+2 
mg/kg M30: similar to STZ. STZ+10 mg/kg 
M30: not different vs. Control in any cycle (all 
adjusted  p>0.05). Reduction greater than in 
STZ in 1
st
 cycle (adjusted  p<0.001), in 
further cycles differences smaller and non-
significant. 
 Learning capacity 
(reduced NoE day 4 vs. 
day 1 of a training cycle) 
in Controls preserved 
over 3 months, although 
absolute change 
decreased due to lower 
day 1 values over time 
(memory). STZ reduced 
learning capacity in 1
st
 
and 2
nd
 cycle, but with 
repeated trainings 
capacity increased, 
comparable to Control, 
yet at a higher level of 
NoE. Larger M30 dose 
antagonized the 
inhibitory effect of STZ. 
Long-term memory 
acquisition/retention. 
Considered were 
values obtained on 
the 1
st
 days of each 
training cycle (2 or 4 
weeks apart; 
depicted in Figure 
1).** 
 NoE decreased over time in all groups (all  
p<0.001), but less for STZ (=-0.020) than for 
Control (=-0.081) (slopes differ p=0.001). 
STZ+2 mg/kg M30 (=-0.024) close to STZ 
(p=0.480), different from Control (p=0.003). 
STZ+10 mg/kg M30 (=-0.048) close to 
Control (p=0.122), different from STZ 
(p=0.010). Progressively more errors with 
STZ vs. Control: 1
st
 cycle RR=2.03, p=0.005; 
2
nd
 RR=8.04, p<001; 3
rd
 RR=17.6, p<0.001; 
4
th
 RR=18.4, p<0.001. STZ+2 mg/kg M30 
similar to STZ at all times. STZ+10 mg/kg 
M30 closer to Control: 1
st
 RR=1.37, p=0.462; 
2
nd
 RR=4.78, p=0.003; 3
rd
 RR=3.90, p=0.213, 
4
th
 RR=2.40, p=0.812; and progressively less 
errors than STZ: 1
st
 RR=0.68, p=0.245; 2
nd
 
RR=0.59, p=0.207; 3
rd
 RR=0.22, p=0.004; 4
th
 
RR=0.13, p=0.026. 
 Training resulted in 
development of memory 
in all groups. Memory 
acquisition/retention was 
greatly reduced by STZ 
(vs. Control). The effect 
of STZ increased over 
time. The effect was 
largely antagonized by 
the higher M30 dose. 
Antagonizing effect also 
increased over time. 
Data are shown for the number of errors (NoE). Escape latency times followed the same patterns (not shown). Effects are expressed as regression 
coefficients of outcomes on time (slopes, ), relative risks (RR) or mean differences () and were adjusted for multiple comparisons. 
 
*General linear mixed model: treatment, time, treatment*time interaction without or with further adjustment for values on day 1 of each cycle (time-varying 
covariate)* 
 *Generalized (Poisson) linear mixed model: treatment, time, treatment*time interaction; for regression slopes, further adjustment for the value on day 1 of the 
1sttraining cycle.
 
 
